Characterization of the chemotactic and mitogenic response of SMCs to PDGF-BB and FGF-2 in fibrin hydrogels

Journal of Biomedical Materials Research - Part A

Volumn 94, Issue 3, 2010, Pages 988-996

  Ucuzian, Areck A ^a   Brewster, Luke P ^b   East, Andrea T ^c   Pang, Yongang ^a   Gassman, Andrew A ^a   Greisler, Howard P ^a,d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Edward E Hines VA Hospital   (United States)

Author keywords

FGF 2; Fibrin; PDGF BB; Smooth muscle cells; Tissue engineering

Indexed keywords

3D CULTURE; BIOCOMPATIBLE SCAFFOLDS; BOYDEN CHAMBER; CHEMOTACTIC RESPONSE; FGF-2; GROWTH FACTOR; MATRIX; MITOGENIC; MITOGENIC RESPONSE; MITOMYCIN C; SMOOTH MUSCLE CELLS; STIMULATED CELLS;

ACTIVATION ANALYSIS; BIOACTIVITY; BIOCHEMISTRY; CELL PROLIFERATION; HYDROGELS; MUSCLE; PEPTIDES; SCAFFOLDS; THREE DIMENSIONAL; TISSUE ENGINEERING;

CELL CULTURE;

FIBRIN; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR BB;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; MITOGENESIS; SMOOTH MUSCLE FIBER;

ANIMALS; CELL CULTURE TECHNIQUES; CHEMOTAXIS; FIBRIN; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYDROGELS; MITOGENS; MITOSIS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLATELET-DERIVED GROWTH FACTOR;

EID: 77954797580     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32786     Document Type: Article

References (53)

1. Zisch AH, Lutolf MP, Hubbell JA. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol 2003;12:295-310.
2. Gray JL, Kang SS, Zenni GC, Kim DU, Kim PI, Burgess WH, Drohan W, Winkles JA, Haudenschild CC, Greisler HP. FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia. J Surg Res 1994;57:596-612.
3. Ehrbar M, Djonov VG, Schnell C, Tschanz SA, Martiny-Baron G, Schenk U, Wood J, Burri PH, Hubbell JA, Zisch AH. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res 2004;94: 1124-1132.
4. Ehrbar M, Zeisberger SM, Raeber GP, Hubbell JA, Schnell C, Zisch AH. The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials 2008;29:1720-1729.
5. Boontheekul T, Mooney DJ. Protein-based signaling systems in tissue engineering. Curr Opin Biotechnol 2003;14:559-565.
6. Gao J, Crapo P, Nerem R, Wang Y. Co-expression of elastin and collagen leads to highly compliant engineered blood vessels. J Biomed Mater Res Part A 2008;85:1120-1128.
7. Ross JJ, Tranquillo RT. ECM gene expression correlates with in vitro tissue growth and development in fibrin gel remodeled by neonatal smooth muscle cells. Matrix Biol J Int Soc Matrix Biol 2003;22:477-490.
8. Long JL, Tranquillo RT. Elastic fiber production in cardiovascular tissue-equivalents. Matrix Biol J Int Soc Matrix Biol 2003;22: 339-350.
9. Grassl ED, Oegema TR, Tranquillo RT. A fibrin-based arterial media equivalent. J Biomed Mater Res Part A 2003;66:550-561.
10. L'Heureux N, Paquet S, Labbe R, Germain L, Auger FA. A completely biological tissue-engineered human blood vessel. FASEB J 1998;12:47-56. (Pubitemid 28060270)
11. Clowes AW. Regulation of smooth muscle cell proliferation and migration. Transplantation Proc 1999;31:810-811.
12. Mitra AK, Del Core MG, Agrawal DK. Cells, cytokines and cellular immunity in the pathogenesis of fibroproliferative vasculopathies. Can J Physiol Pharmacol 2005;83:701-715.
13. Lin H, Chen B, Sun W, Zhao W, Zhao Y, Dai J. The effect of collagen- targeting platelet-derived growth factor on cellularization and vascularization of collagen scaffolds. Biomaterials 2006;27: 5708-5714.
14. Zhao W, Chen B, Li X, Lin H, Sun W, Zhao Y, Wang B, Han Q, Dai J. Vascularization and cellularization of collagen scaffolds incorporated with two different collagen-targeting human basic fibroblast growth factors. J Biomed Mater Res A 2007;82: 630-636.
15. Chen RR, Silva EA, Yuen WW, Mooney DJ. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 2007;24:258-264.
16. Atluri P, Woo YJ. Pro-angiogenic cytokines as cardiovascular therapeutics: Assessing the potential. BioDrugs 2008;22:209-222.
17. Brewster LP, Brey EM, Tassiopoulos AK, Xue L, Maddox E, Armistead D, Burgess WH, Greisler HP. Heparin-independent mitogenicity in an endothelial and smooth muscle cell chimeric growth factor (S130K-HBGAM). Am J Surg 2004;188:575-579.
18. Uriel S, Brey EM, Greisler HP. Sustained low levels of fibroblast growth factor-1 promote persistent microvascular network formation. Am J Surgery 2006;192:604-609.
19. Pang Y, Ucuzian AA, Matsumura A, Brey EM, Gassman AA, Husak VA, Greisler HP. The temporal and spatial dynamics of microscale collagen scaffold remodeling by smooth muscle cells. Biomaterials 2009;30:2023-2031.
20. Shireman PK, Xue L, Maddox E, Burgess WH, Greisler HP. The S130K fibroblast growth factor-1 mutant induces heparin-independent proliferation and is resistant to thrombin degradation in fibrin glue. J Vasc Surg 2000;31:382-390. (Pubitemid 30100047)
21. Brewster LP, Washington C, Brey EM, Gassman A, Subramanian A, Calceterra J, Wolf W, Hall CL, Velander WH, Burgess WH, Greisler HP. Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen. Biomaterials 2008;29:327-336.
22. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992;89:507-511.
23. Lindner V, Olson NE, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J Clin Invest 1992;90: 2044-2049.
24. Reidy MA. Neointimal proliferation: The role of basic FGF on vascular smooth muscle cell proliferation. Thromb Haemostasis 1993; 70:172-176. (Pubitemid 23225474)
25. Lewis CD, Olson NE, Raines EW, Reidy MA, Jackson CL. Modulation of smooth muscle proliferation in rat carotid artery by platelet- derived mediators and fibroblast growth factor-2. Platelets 2001;12:352-358.
26. Vaina S, Serruys PW. Progressive stent technologies: New approaches for the treatment of cardiovascular diseases. Expert Opin Drug Deliv 2006;3:783-797.
27. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR- 1 activation. Circ Res 2005;96:172.
28. Facchiano A, De Marchis F, Turchetti E, Facchiano F, Guglielmi M, Denaro A, Palumbo R, Scoccianti M, Capogrossi MC. The chemotactic and mitogenic effects of platelet-derived growth factor-BB on rat aorta smooth muscle cells are inhibited by basic fibroblast growth factor. J Cell Sci 2000;113:2855-2863.
29. Schollmann C, Grugel R, Tatje D, Hoppe J, Folkman J, Marme D, Weich HA. Basic fibroblast growth factor modulates the mitogenic potency of the platelet-derived growth factor (PDGF) isoforms by specific upregulation of the PDGF alpha receptor in vascular smooth muscle cells. J Biol Chem 1992;267:18032-18039.
30. Zimmermann O, Zwaka TP, Marx N, Torzewski M, Bucher A, Guilliard P, Hannekum A, Hombach V, Torzewski J. Serum starvation and growth factor receptor expression in vascular smooth muscle cells. J Vasc Res 2006;43:157-165.
31. Hall H. Modified fibrin hydrogel matrices: Both, 3D-scaffolds and local and controlled release systems to stimulate angiogenesis. Curr Pharm Des 2007;13:3597-3607.
32. Mol A, Van Lieshout MI, Dam-De Veen CG, Neuenschwander S, Hoerstrup SP, Baaijens FP, Bouten CV. Fibrin as a cell carrier in cardiovascular tissue engineering applications. Biomaterials 2005; 26:3113-3121.
33. Cummings CL, Gawlitta D, Nerem RM, Stegemann JP. Properties of engineered vascular constructs made from collagen, fibrin, and collagen-fibrin mixtures. Biomaterials 2004;25:3699-3706.
34. Syedain ZH, Weinberg JS, Tranquillo RT. Cyclic distension of fibrin-based tissue constructs: Evidence of adaptation during growth of engineered connective tissue. Proc Natl Acad Sci USA 2008;105:6537-6542.
35. Shaikh FM, Callanan A, Kavanagh EG, Burke PE, Grace PA, Mcgloughlin TM. Fibrin: A natural biodegradable scaffold in vascular tissue engineering. Cells Tissues organs 2008;188:333-346.
36. Swartz DD, Russell JA, Andreadis ST. Engineering of fibrin-based functional and implantable small-diameter blood vessels. Am J Physiol Heart Circ Physiol 2005;288:H1451-H1460.
37. Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 2008;6:176-183.
38. Sahni A, Khorana AA, Baggs RB, Peng H, Francis CW. FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood 2006;107:126-131.
39. Duarte M, Kolev V, Kacer D, Mouta-Bellum C, Soldi R, Graziani I, Kirov A, Friesel R, Liaw L, Small D, Verdi J, Maciag T, Prudovsky I. Novel cross-talk between three cardiovascular regulators: Thrombin cleavage fragment of Jagged1 induces fibroblast growth factor 1 expression and release. Mol Biol Cell 2008;19:4863-4874.
40. Cao H, Dronadula N, Rao GN. Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells. Am J Physiol Cell Physiol 2006;290:C172-182.
41. Bassus S, Herkert O, Kronemann N, Gorlach A, Bremerich D, Kirchmaier CM, Busse R, Schini-Kerth VB. Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: Role of reactive oxygen species. Arterioscler Thromb Vasc Biol 2001;21:1550-1555.
42. Rauch BH, Millette E, Kenagy RD, Daum G, Clowes AW. Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res 2004;94:340.
43. Rowe SL, Lee S, Stegemann JP. Influence of thrombin concentration on the mechanical and morphological properties of cell-seeded fibrin hydrogels. Acta Biomater 2007;3:59-67.
44. Millette E, Rauch BH, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB transactivates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells. Trends Cardiovasc medice 2006;16:25-28.
45. Pintucci G, Yu PJ, Saponara F, Kadian-Dodov DL, Galloway AC, Mignatti P. PDGF-BB induces vascular smooth muscle cell expression of high molecular weight FGF-2, which accumulates in the nucleus. J Cell Biochem 2005;95:1292-1300.
46. Pickering JG, Uniyal S, Ford CM, Chau T, Laurin MA, Chow LH, Ellis CG, Fish J, Chan BM. Fibroblast growth factor-2 potentiates vascular smooth muscle cell migration to platelet-derived growth factor: Upregulation of alpha2beta1 integrin and disassembly of actin filaments. Circ Res 1997;80:627-637.
47. Thie M, Harrach B, Schonherr E, Kresse H, Robenek H, Rauterberg J. Responsiveness of aortic smooth muscle cells to soluble growth mediators is influenced by cell-matrix contact. Arterioscler Thromb 1993;13:994-1004. (Pubitemid 23195801)
48. Thie M, Schlumberger W, Semich R, Rauterberg J, Robenek H. Aortic smooth muscle cells in collagen lattice culture: Effects on ultrastructure, proliferation and collagen synthesis. Eur J Cell Biol 1991;55:295-304.
49. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nature reviews. Mol Cell Biol 2006;7:211-224.
50. Stegemann JP, Hong H, Nerem RM. Mechanical, biochemical, and extracellular matrix effects on vascular smooth muscle cell phenotype. J Appl Physiol 2005;98:2321-2327.
51. Rensen SS, Doevendans PA, Van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Nerls Heart J 2007;15:100-108.
52. Stegemann JP, Nerem RM. Altered response of vascular smooth muscle cells to exogenous biochemical stimulation in two- and three-dimensional culture. Exp Cell Res 2003;283:146-155.
53. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. journal of vascular surgery: Official publication, the society for vascular surgery [and] international society for cardiovascular surgery. North Am Chapter 2007; 45(Suppl A):A25.